Earnings Watch -- WSJ
26 Octubre 2016 - 2:03AM
Noticias Dow Jones
PROCTER & GAMBLE
Pampers Maker Enjoys Higher Sales
Procter & Gamble Co. increased sales of staples from laundry
detergent to toothpaste in the most recent quarter, which boosted
the company's shares despite a warning that growth will be spotty
in the months ahead.
The maker of Gillette razors and Pampers diapers on Tuesday
posted an unexpected rise in profit for the quarter and said
organic sales -- a closely watched metric that strips out currency
moves, acquisitions and divestments -- grew 3%, the biggest
increase in more than a year. In 4 p.m. New York trading Tuesday,
the company's shares were up 3.4% at $86.97.
In all for the latest quarter, P&G reported profit of $2.71
billion for the first quarter ended Sept. 30, up 4.2% from a year
earlier. Revenue was essentially flat at $16.5 billion.
The company backed its 2017 forecast for per-share earnings
growth in the mid-single digits from fiscal 2016 and sales growth
of about 1%.
--Sharon Terlep and Anne Steel
UNITED TECHNOLOGIES
Profit Rises Despite Cost of Engine Rollout
United Technologies Corp. reported strong earnings and sales
growth, dodging pressure that has hurt rival industrial firms, even
as it struggles with the rollout of its new jet engine.
The third quarter showed that the company has been able to
balance out the rising cost of making the new jet engine -- the
product of more than a decade and $10 billion in investment -- with
strong performance across its other businesses, including its air
conditioning and building controls businesses and its aerospace
systems maker.
"Balance still works at UTC," Chief Executive Gregory Hayes said
on a conference call. Shares of the company rose about 1.85%,
closing at $101.36.
The company reported a 8.7% increase in third-quarter profit
while revenue grew 4.1% to $14.35 billion. The company raised its
2016 profit and sales forecasts.
At the same time, the company warned that profits will be flat
next year, weighed down by costs of building new jet engines and
clawing back market share for elevators.
--Anne Steele
MERCK
Cancer Drug Sales Provide a Boost
Merck & Co. posted increases in third-quarter revenue and
profit, helped by higher sales of a closely watched cancer
treatment and vaccines. Merck is trying to overcome pressure on
sales of its top products. The Kenilworth, N.J., company is
counting on rising sales of its new cancer drug Keytruda.
For the third quarter, Keytruda posted sales of $356 million, up
from $159 million in the same quarter last year.
The company posted a profit in the quarter of $2.18 billion, or
78 cents a share, up from $1.83 billion, or 64 cents a share, a
year prior. Excluding restructuring and acquisition-related costs
and other items, per-share earnings rose to $1.07 from 96 cents.
Sales grew 4.6% to $10.54 billion.
Analysts polled by Thomson Reuters had forecast per-share
earnings of 99 cents a share on revenue of $10.18 billion.
For the year, Merck now projects per-share adjusted earnings
between $3.71 and $3.78 on revenue between $39.7 billion and $40.2
billion. It had previously expected earnings of $3.67 to $3.77 and
revenue of $39.1 billion to $40.1 billion.
--Peter Loftus and Austen Hufford
(END) Dow Jones Newswires
October 26, 2016 02:48 ET (06:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
United Technologies (NYSE:UTX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
United Technologies (NYSE:UTX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024